BACKGROUND: Stereoelectroencephalography (SEEG) has been shown to be a valuable tool for the anatomoelectroclinical definition of the epileptogenic zone (EZ) in patients with medically refractory epilepsy considered for surgery (RES patients). In Spain, many of those patients are not offered this diagnostic procedure. OBJECTIVE: To evaluate the effectiveness, safety, and cost-effectiveness of SEEG to define the EZ in RES patients compared to no SEEG intervention, ie, remaining with further antiepileptic drugs.
D
uring the presurgical evaluation of refractory epilepsy patients considered for surgery (RES patients), the assessment of the extent of the epileptogenic zone (EZ) and its organization is a crucial requirement. When the noninvasive There are several modalities of invasive EEG depending on the type of electrodes and the specific implantation technique used. 1 Intracerebral electrodes stereotactically inserted through a twist drill hole or burr hole constitute the so-called depth electrodes. The methodology of implantation and definition of their anatomical localization (without combining them with subdural electrodes) follow a very specific theoretical model that seeks to establish the anatomoelectroclinical correlate of the seizures is the so-called stereoelectroencephalography (SEEG). [2] [3] [4] Most centres in Europe who developed this approach do not use other form of invasive diagnosis because the methodological definition excludes the combination with subdural electrodes. [5] [6] [7] [8] SEEG can be applied to most indications of invasive EEG and offer specific indications of use that distinguish it from other methodologies of implantation such as the subdural electrodes. [9] [10] [11] In Spain, RES patients are usually referred to epilepsy monitoring units (EMUs). SEEG is currently available, in a systematic basis, in only 3 of the 8 existing National Health Service (NHS)-accredited EMUs in Spain. Therefore, in our country, many patients who require SEEG monitoring to provide the most correct diagnosis are not offered this technology and continued with further antiepileptic drugs (AEDs) treatment. Besides these territorial access limitations, a valid pooled analysis on the effectiveness, safety, and cost-effectiveness of SEEG is lacking. 12 The aim of the present study is to identify, critically assess, and synthesize available scientific evidence on the effectiveness and safety of SEEG to define the EZ in RES patients and also to conduct an integrated economic evaluation incorporating information of health outcomes and costs of SEEG compared to no SEEG intervention, ie, remaining with further AEDs treatment, due to lack of access to this methodology in most centers in Spain.
METHODS

Effectiveness and Safety
A systematic review was developed and is reported in accordance to PRISMA 13 and MOOSE recommendations. 14 
Information Sources and Search Strategy
The following databases were searched (April 2016): Medline and PreMedline, EMBASE, SCI-EXPANDED, SSCI, and the Cochrane Library, limited to trials. The search strategy was developed initially in Medline using controlled vocabulary and free text terms and then it was adapted for each of the other databases. Search terms included the following: epilepsy, SEEG, and neurosurgical procedures. The search was limited to the English and Spanish languages and no date restriction was imposed. Medline search strategy is available in Table, Supplemental Digital Content 1. Full search strategies are available from the study authors.
Reference lists of all relevant papers were manually examined to identify possible additional studies not retrieved by the electronic search.
Selection Criteria
Experimental, quasiexperimental, and observational studies published in English or Spanish, which assessed the effectiveness or safety of SEEG to anatomically define the EZ in adults or children with RES, were included. Comparison group could receive an alternative diagnostic strategy or the maintenance of AEDs treatment (patients not suitable for surgery). Studies with less than 20 participants were excluded. Studies not reporting any subsequent decision regarding surgery or surgical outcome were also excluded. Any patient-related outcome was considered, including Engel's classification of seizure outcome, as well as outcomes related to seizure activity, functional capacity, patient-related quality of life, and adverse events. Studies with results restricted to patients who had a good (or bad) outcome after surgery were excluded.
Screening Process
Titles and abstracts of the references identified were evaluated independently by 2 reviewers. The full text of those studies which appeared to fulfill prespecified selection criteria was read and evaluated for inclusion. Doubts and discrepancies between reviewers were resolved through discussion with the research team.
Data Collection Process and Quality Assessment
A data extraction form was developed by the authors, pilot-tested on 2 studies, and refined accordingly. One review author extracted the following data from included studies: study details (author, year, study design, country of study), participant details (selection criteria, demographics, duration of epilepsy), methodology of SEEG (preoperative imaging, total number of electrodes implanted, operative time, duration of monitoring), surgery details (number of patients who underwent surgery, type of surgery), outcome following surgery details, and complications (both of SEEG and surgery). A second reviewer subsequently verified the extracted data. When some required information was missing or unclear in the published article, an effort was made to contact authors.
Two reviewers independently assessed the quality of included studies using the criteria of The Cochrane Collaboration's tools for assessing risk of bias for randomized controlled trials 15 and nonrandomized studies of interventions. 16 Any doubts or disagreements between both reviewers were resolved first by verifying the protocol criteria and subsequently by consensus.
According to the recommendations of the Cochrane Collaboration, funnel plot was used to estimate potential publication bias case, there were 10 or more studies that could be combined. 15 
Statistical Analysis
Meta-analyses were performed for the identification of the EZ by SEEG, treatment decision, result of surgery, and reported complications. Due to the lack of control groups in all included studies it was not possible to calculate relative risk ratios. Consequently, pooled proportions and forest plots were performed based on Stata version 14 (StataCorp, College Station, Texas), using the program metaprop_one. 17 Pooled proportions were analysed using the logistic-normal randomeffects model with the Freeman-Tukey double arcsine transformation. The confidence intervals for the individual studies were also computed with the exact method. Zero event studies were included and excluded in our analysis. Results among studies were compared with 95% CIs and forest plots. To assess heterogeneity between individual studies, χ 2 statistic and I 2 value were calculated within each outcome's meta-analysis.
When the number of includes studies was more than 10 and substantial heterogeneity was observed, we planned to perform subgroup analyses and meta-regression analyses to explore the potential source of heterogeneity based on type of intervention, localization of EZ, magnetic resonance imaging (MRI) results (MRI-positive vs MRInegative), population age (children aged ≥17 yr, adults ≥18 yr, or both), study design, and year of publication (≤2000 or >2000).
Economic Evaluation
A full economic assessment of health outcomes and costs of SEEG vs no SEEG (therefore continuing with further AEDs therapy) for patients in Spain were conducted. The analysis took the perspective of the NHS, therefore only direct costs incurred by the Spanish NHS were included. Effectiveness was measured in terms of quality-adjusted life years (QALYs). [18] [19] [20] Costs (in EUR 2017) and benefits (QALYs) were discounted at an annual rate of 3%. 19 The cost-effectiveness analysis was based on a decision tree together with a Markov model which simulates the costs and health outcomes of one cohort of 1000 patients treated under these alternatives for a lifetime horizon, using annual cycles.
Cost-effectiveness was summarized as the incremental costeffectiveness ratio (ICER). [18] [19] [20] The ICER is then compared with the decision makers' willingness-to-pay threshold to draw conclusions about the cost-effectiveness of the intervention. In Spain, the only estimated threshold value ranges between 20 000 and 25 000 EUR per QALY. 21 We developed a deterministic scenario and a probabilistic sensitivity analysis (PSA), in order to characterize the uncertainty in the model results. We graphically represented the uncertainty by means of the cost-effectiveness planes and the cost-effectiveness acceptability curves (CEACs).
Model Structure
The model was based on 2 related structures, a decision tree for the short-term together with a Markov model for the long-term. A simplified form of both structures is shown in Figures 1A and 1B , respectively. The health states were defined based on a previous cost-effectiveness analysis of the alternative technologies used to visualize EZ (except SEEG), which describe the long-term natural history of RES patients. 12 The starting point were individuals diagnosed with RES. Patients within the population of interest were aged 26 yr, based on the mean age observed in the meta-analyses used to obtain the effectiveness parameters. They all suffer from disabling seizures. They may become seizure free either through surgery after EZ location by SEEG monitoring or for continuing the AEDs therapy. After the first year, a seizure-free patient may stay either at the "seizure free" health state or return to the "disabling seizure" health state. Also, a patient with disabled seizure may change to the "seizure free" health state at some point. The model distinguishes how long the patient has been in the "seizure free" health state, mainly 1, 2, or more than 2 yr, due to the need to continue the AEDs treatment. During the first 5 yr after each intervention, a patient with seizure freedom may suffer from disabling seizures again and change to the health state "disabling seizure." Patients have a risk of mortality independent of RES based on general population mortality rates and increased mortality risks associated to the health states and interventions considered.
Transition Probabilities, Mortality Risks, and Relative Risks
Annual transitions probabilities that characterize the natural history of RES patients were taken from Bruch et al 12 and from their identified sources. 22 See Table, Supplemental Digital Content 2. Mortality rates for the general population were based on the Spanish life tables published by National Statistics Institute (http://www.ine.es/en). Increased mortality risks related to the health states belonging to the natural history of RES were drawn from Bruch et al 12 and from their identified source 22 (see Table, Supplemental Digital Content 2).
The evidence on the effectiveness of SEEG and surgery for the first year was based on our meta-analyses. The effectiveness of the AEDs therapy was based on a recent systematic review. 23 All these measures are presented in Table 1 .
Resource Use and Unit Costs
Information on the use of healthcare resources for each intervention and their unit costs were obtained from an exhaustive systematic review of the literature 24 and the RECHOP database (Red Española de Costes Hospitalarios). 25 The use of SEEG implies not only the intervention itself, such as the use of an operating theater, specialized electrodes and human resources, but also the use of pre-and postintervention resources such as visits to the specialist, magnetic resonances, monitoring time in hospital, etc. The AEDs therapy implies not only the AEDs but also a follow-up care based on specialist visits.
We note that patients moving to a disabling seizure state must continue 2 yr under AEDs therapy. Then, some of them, from the third year start a progressive dose reduction for 2 yr until eliminating the treatment. The proportion of patients that begin this reduction is 15.7%. 26 The cost of each health state was measured as the cost associated with the burden of the disease according to the healthcare service, diagnostic tests, and the treatment associated with the chosen alternative.
Quality-Adjusted Life Years
Effectiveness was measured using QALYs. QALY is a measure of health-related quality of life (HRQoL), which combines information on QoL and length of life and is widely recommended in economic evaluations to facilitate comparable decisions about resource allocation under different health conditions. 18, 19 QALYs are measured in terms of utility on a cardinal scale of 0 to 1, where 0 indicates death and 1 indicates full health, grounded in decision science and expected utility theory. In order to estimate the number of QALYs related to each intervention, we attached HRQoL values (utilities) to each health state included in our model. To do this, disutility values based on EQ-5D scores were drawn from the Burch et al 12 and its identified source. 22 Disutility values were subtracted from the average norm of the Spanish adult population (0.91) based on the information provided by a nationally representative survey conducted in Spain (http://www.msssi.gob.es/en/estadEstudios/estadisticas/ encuestaNacional/encuesta2011.htm). 
Sensitivity Analysis
Deterministic Sensitivity Analysis: Deterministic sensitivity analyses were performed to explore the impact of those parameters with the highest level of uncertainty. In order to set the limits of the sensitivity analyses we considered information from alternative sources of the scientific literature and assumptions stated by experts. Table 2 shows the parameters that were varied, the proposed scenarios, and their limits; including the discount rate and the mean age of patients. We also varied the costs, utilities, and increase mortality risks accounting for higher uncertainty. Furthermore, we conducted a series of conservative scenario analyses where we used the lower and upper limit of the 95% confident interval of a set of parameters: (1) the increase mortality rates, (2) the disutilities and (3) the costs.
Probability Sensitivity Analysis: To characterize the uncertainty in the model, we undertook a PSA using Monte Carlo simulation. We applied probability distributions to each parameter depending on its nature according to the Economic Evaluation Guidelines. 18, 19, 27 See Table 1 and Table, Supplemental Digital Content 2 for further details.
We ran 10 000 simulations in the Monte Carlo analysis. For each simulation we obtained the mean cost and QALY of each alternative that we graphically represented in the cost-effectiveness plane. These simulations were also used to compute the CEACs, which show the probability of each alternative of being cost-effective for different values of willingness to pay per QALY, in other words, the percentage of Monte Carlo simulations above and below different cost-effectiveness thresholds.
RESULTS
Effectiveness and Safety
The results of the literature search and study selection process are shown in Figure 2 . Of a total of 1061 references retrieved once the duplicates were removed, 33 studies (39 papers) published in English were finally eligible for inclusion. 5, On the basis of the full paper examination, 123 studies were excluded (see Figure 2) .
Characteristics of Included Studies
The main characteristics of selected studies are summarized in Table 3 . All studies were uncontrolled observational studies, 23 of them were retrospective reviews (mean follow-up time: 23.4 mo), and 10 prospective studies (mean follow-up time: 28.7 mo). The 33 studies enrolled a total of 2959 participants who underwent a SEEG study. Study size was highly variable, ranging from 20 to 582 participants, with an average of 90 participants per study. The ages of participants were also widely distributed, ranging from 5 mo to 69 yr. The mean age was 27.35 ± 6.27 yr; 46% were female.
A total of 18 200 electrodes were implanted with a mean number of electrodes per patient of 11.3. The mean time of implantation of the electrodes was 198 min (range: 45-480) and the mean recording time was 10.76 d (range: 2-30). Only 13 studies reported performing MRI in the presurgical workup. 28, 29, 32, 34, 35, 38, 39, 45, 53, 54, [61] [62] [63] Patients were classified according to surgery outcome into: patients with a class I Engel, patients with a class I or II Engel outcome or >90% reduction in seizure following surgery (regarded as good outcome), and patients with a class III or IV Engel outcome or <90% reduction in seizure following surgery (regarded as bad outcome). When studies either did not report outcome according to Engel's classification or only provided data grouped according to Engel class I or class II to IV, then the closest approximation to Engel I and II and Engel III and IV was extracted.
The results of the methodological quality assessment of the included studies are shown in Table 4 . The quality of the overall evidence was considered low.
According to funnel plots, no publication bias was observed (see Figure, Supplemental Digital Content 3) .
Syntheses of Results
All results of meta-analyses including and excluding zero event studies are shown in Decision for Surgery: The 72% (1135/1578) of patients who underwent the SEEG study were eligible for epilepsy surgery (95% CI: 0.66-0.78), 78.85% of them for resective surgery, 16.83% for radiofrequency thermocoagulation (RFTC), and 4.32% for both procedures.
Outcome of Surgery: A total of 669 patients of 868 who underwent SEEG to determine whether or not they were eligible for epilepsy surgery were free of seizures after surgery (pooled prevalence: 33%; 95% CI: 0.27-0.42) with expected heterogeneity by intervention groups (surgical resection, RFTC or both; see The subgroup analyses suggested no significant association between the population age, study design, or year of publication, and the prevalence of patients who received SEEG and were free of seizures after surgery in each subgroup (even if only those who received surgery are considered). No substantial source of heterogeneity was found by meta-regression analyses.
Subgroups and meta-regression based on localization of EZ and MRI could not be performed because data were not available.
A good outcome after surgery was obtained in 45% of patients who underwent SEEG (95% CI: 0.38-0.53) and in 66% when taking into account only patients who underwent surgical resection, RFTC or both (95% CI: 0.55-0.75).
Mortality: A total of 6 deaths occurred among the total of 2959 participants who were studied by SEEG, with no statistical heterogeneity between studies (I 2 = 0%; P = 0.99). Safety: A pooled prevalence of 1.3% (95% CI: 0.01-0.02) for all complications related to insertion/monitoring SEEG, and the subsequent intervention was obtained. Hemorrhagic complications were those reported most frequently (pooled prevalence: 2%; 95% CI: 0.01-0.02; I 2 = 3.70%, P = .41). Among them, intracerebral bleeding was the most common type (pooled prevalence: 1%; 95% CI: 0.00-0.01; I 2 = 0.00%, P = .66). Infections were the second most frequent complications (pooled prevalence: 1%; 95% CI: 0.00-0.01; I 2 = 25.09%, P = .21). Among them, superficial infections and brain abscesses were the most common. In total, 20 patients had permanent neurological deficits (pooled prevalence: 1%; 95% CI: 0.00-0.03; I 2 = 59.90%, P = .008) and 17 patients had transient neurological complications (weakness or change sensory; pooled prevalence: 1%; 95% CI: 0.00-0.02; I 2 = 49.30%, P = .02).
Economic Evaluation
The results of the analysis are shown in Table 2 , showing the lifetime costs and QALYs for RES patients. The mean incremental cost per patient using SEEG compared with AEDs is estimated in 93 998 EUR. The estimated mean incremental QALY per patient gain of using SEEG is 9.07 QALYs per patient, which leads to an ICER of 10 368 EUR per QALY. The deterministic sensitivity analysis is shown in Table 2 . The results show that the variation of these parameters does not significantly affect the ICER. The same occurs when the discount rate decreases and when the average age patient increases. When we explore different scenarios (1, 2, and 3) varying the values of costs, disutilities, and increased mortality risks, the ICERs remain stable.
The PSA graphically shows the uncertainty with respect to costs and QALYs related to each strategy. Figure 3A represents the Monte Carlo simulations estimating a 95% confident interval (CI) which ranges from the SEEG as a dominant strategy (less costly and more effective) up to 113 911 EUR per QALY (see Table 2 ). However, most of the Monte Carlo simulations are largely below 25 000 EUR per QALY, which is showed by the CEACs in Figure 3B . Then, given the willingness to pay of 20 000 and 25 000 EUR per QALY, 21 the probability of the SEEG of being cost-effective is 75% and 88%, respectively. In other words, the number of Monte Carlo simulations below the costeffectiveness threshold of 20 000 and 25 000 EUR per QALY 21 is 750 and 880, respectively. 
DISCUSSION
Invasive diagnostic is necessary in 25% to 50% of RES patients for the correct identification of the EZ. 5, 65, 66 SEEG is an implantation methodology developed in the 60s in France whose use has steadily increased in the last decade for the rest of the world. [6] [7] [8] 38 SEEG seems to offer specific indications of use that distinguish it from other methodologies of implantation such as the subdural electrodes.
1 First, its ability to access deep cortical structures that cannot be evaluated through studies with subdural electrodes. In scenarios in which bilateral implantation is required, the SEEG becomes the preferred modality, avoiding or reducing the need of bilateral craniotomy. Moreover, eloquent brain areas such as language, motor or the sensory cortex can be studied by SEEG allowing its delimitation before surgery. Additionally, due to its modality of implantation, SEEG is the unique technique that can evaluate 3D cerebral volumes (as opposed to subdural grids that evaluate only 2D cerebral surfaces) in order to establish an anatomical correlate of the origin and the propagation of seizures.
5 SEEG allows studying the spatiotemporal dynamics of seizure discharges related to semiologic ictal evolution with a high degree of anatomical precision. Finally, SEEG allows evaluation in a series of conditions not easily assessed with subdural electrodes and most of the time precluded for resective surgery such as polymicrogyria, tuberous sclerosis complex, depth focal cortical dysplasia, periventricular heterotopias, and MRI-negative epilepsy.
The results of our meta-analyses show that SEEG can be a useful and safe method for the localization of the EZ in RES patients. Those participants who underwent SEEG showed a high rate of EZ localization and around 3 quarters of patients were eligible for epilepsy surgery. In 92% of cases in which SEEG was utilized, the EZ was found. However, this finding is principally reached by centers with years if not decades of experience in the technique. Lower statistics would be more realistic at the beginning of its adoption. 63 However, it was not an objective of this study to achieve comparative results with other invasive diagnostic techniques in terms of effectiveness in EZ localization. Indeed, a study of such characteristics in which different surgical implantation techniques are compared is in methodological and ethical terms not feasible.
In our study, one-third of patients were free of seizures after surgical resection, RFTC or both, and approximately a half reduced seizures by more than 90% irrespective if they were operated or not. This means good chances of success only by choosing patients who are candidates for implantation. Furthermore, 47% of patients remained seizure-free after surgery. Other interesting aspect of this methodology, not addressed in our study, is the possibility to perform RFTC in implanted patients. 67 The efficacy in the seizure control reach until of 58% of responders. 68 This could also have an impact in terms of safety and cost-efficacy when a resective surgery is finally avoided.
Rate of total complications associated with SEEG and the subsequent intervention was low (pooled prevalence: 1.3%), similarly to previous studies in the recent literature. 69 This is especially lower compared with previous published results with subdural electrodes which reach complication's rates ranging from 11% to 19%, although the rate of permanent neurological deficits seems to be similar. 70, 71 Overall, the mortality rate (0.2%) seems to be lower considered the available evidence. However, the severity of the individual hemorrhagic complications is not possibly to estimate between techniques.
To the best of our knowledge, no previous studies have carried out a cost-effectiveness analysis of SEEG. The absence of such studies demonstrates the need to evaluate SEEG in patients with RES.
Our results show that the SEEG monitoring ultimately followed by surgery is more effective for RES patients to become seizure free than remaining with further AEDs; however, it is also significantly costlier in Spain.
We estimated an ICER of 10 368 EUR per QALY, which is considerably below the estimated threshold in Spain which ranges between 20 000 and 25 000 EUR per QALY. 21 Therefore, the SEEG is a cost-effective technology from the NHS perspective for RES patients when compared to nonintervention, ie, remaining with further AEDs due to no access to SEEG in Spain. The deterministic sensitivity analyses regarding the discount rate and the mean age of patients show ICERs largely below the costeffectiveness threshold. The PSA estimates a 95% CI ranging from the SEEG as a dominant strategy up to 113 911 EUR per QALY, despite this wide 95% CI, the CEACs show that the probability of the SEEG of being cost-effective is 75% and 88%, respectively. These figures show the robustness of the base case study. This conclusion still remains when different scenarios concerning costs, disutilities, and increase relative risks were considered.
Limitations
Several limitations of this study should be considered. In the analysis of the evidence, mainly the lack of control groups in included studies and the low methodological quality of many of them could be seen as the limitation. We could not perform subgroups analyses based on localization of EZ and MRI. However, we conducted subgroup analyses by population's age, study design, and year of publication, and finding no substantial factors influencing the results. Arguably, some assumptions were undertaken due to the lack of information based on the expert views. Particularly, it was assumed that patients under the SEEG alternative who were not under operation had the same disutility values as the AEDs branch, both for "seizure free" and "disabling seizure" health states. It was also assumed that patients under the SEEG alternative who were under operation but continuing with disabling seizures presented the same disutility values as the AEDs branch with disabling seizure. Finally, it was assumed that patients under the SEEG alternative who were not under operation had the same increased mortality rate values as under AEDs, both for "seizure free" and "disabling seizure" health states. Regarding the AEDs effectiveness, we are aware that the systematic review of Nair 23 presents its own limitations, although being the most recent reference. Another limitation of our study is the lack of use of a control group with other technique such as the use of subdural electrodes. This was due to the objective of our study that was to establish the cost-effectiveness and safety analysis compared to nonintervention in the case of nonavailability of the technique. We acknowledge that some cases could be studied both with subdural electrodes or SEEG. Therefore, we refused to reach any comparative conclusion regarding other technologies in terms of safety or cost-efficacy.
Nonetheless, despite all these limitations this study is the first to provide assessment on the cost-effectiveness of the SEEG, also including parameters supported by the meta-analyses conducted within the study.
CONCLUSION
According to our results, we conclude that SEEG is a costeffective technology in RES patients when compared to nonintervention, ie, remaining with further AEDs treatment. These results are internationally innovative.
